Status:
COMPLETED
A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential
Lead Sponsor:
Genentech, Inc.
Conditions:
Healthy
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
This is an open-label, Phase I, single-center, single-dose administration study to determine the absolute bioavailability, clearance, and volume of distribution of GDC-0449 (Part A) and to determine t...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Female
- Non-childbearing potential
- Body mass index (BMI) between 18 and 32 kg/m\^2, inclusive
- In good health, determined by no clinically significant findings on physical examination, medical history, 12-lead ECG, and vital signs
- Negative test for drugs of abuse at screening (does not include alcohol) and at admission to the clinical research facility (does include alcohol)
- Exclusion Criteria
- History or clinical manifestations of clinically significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urologic, neurologic, inflammatory, or psychiatric disorders, or cancer
- History of symptomatic hypotension, idiopathic orthostatic hypotension, or other autonomous-failure syndromes
- History of severe physical injury, direct impact trauma, or neurological trauma within 6 months prior to Day -1
- History of stomach or intestinal surgery, stomach disease, or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy are allowed)
- History of alcoholism, drug abuse, or drug addiction (including soft drugs like cannabis products)
- Use of any prescription medications/products, including known enzyme-inducing/inhibiting agents, over-the-counter medication, or other non-prescription preparations (including supplements, vitamins, minerals, phytotherapeutic/herbal/ plant-derived preparations, the tryptophans, and St. John's wort or other hypericum perforatum-containing substance) within 2 weeks prior to Day -1, with the exception of hormone-replacement therapy
- Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 60 days prior to Day -1 or within 5 times the elimination half-life of the respective drug; participation in a trial involving administration of \^1\^4C-radiolabeled compound(s) within 6 months prior to Day -1; participation in more than two other drug trials within 1 year prior to Day -1
- Receipt of any vaccination or immunization within 1 month prior to Day -1
- Use of any nicotine-containing or nicotine-replacement products within 6 months prior to Day -1
- Consumption of alcohol or methylxanthine-containing beverages or food
- Receipt of blood products within 2 months prior to Day -1
- Donation of \> 100 mL of blood within 60 days prior to Day -1; donation of \> 1.0 litres of blood within 10 months prior to Day -1
- Irregular defecation pattern, i.e., less than once per 2 days within 6 months prior to Day -1; acute constipation problems within 3 weeks prior to Day -1 (Part B subjects only)
- Poor peripheral venous access
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00991718
Start Date
September 1 2009
End Date
August 1 2010
Last Update
June 26 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.